论文部分内容阅读
癫是神经科的常见病,多数患者预后良好。但仍有20%~30%的患者经正规抗癫药物规范治疗2 a后不能有效控制成为难治性癫。血脑脊液屏障某些转运蛋白可能参与难治性癫耐药的机制,如P-糖蛋白、乳腺癌耐药蛋白、多药耐药相关蛋白等,且这些转运蛋白抑制剂如维拉帕米、丙磺舒等可能对难治性癫的治疗有帮助。现就这些转运蛋白与难治性癫耐药的关系做一综述。
Epilepsy is a common neurological department, most patients with good prognosis. However, there are still 20% to 30% of patients after formal antiepileptic drug treatment for 2 a can not effectively control the formation of refractory epilepsy. Blood-cerebrospinal fluid barrier Some transporters may be involved in the mechanisms of refractory epilepsy, such as P-glycoprotein, breast cancer resistance protein, multidrug resistance-related protein and the like, and these transporter inhibitors such as verapamil Probenecid may be helpful in the treatment of refractory epilepsy. The relationship between these transporters and refractory epilepsy is now reviewed.